Johansson 1998.

Methods	Setting: Sweden, primary/secondary care unclear Design: parallel group Length of intervention period: 12 weeks Randomisation: yes, method not stated Allocation concealment: unclear Masking: double blind Excluded: not stated Withdrawals: not stated Baseline characteristics: no demographic data presented Jadad score: 2
Participants	219 subjects Age range: not stated Inclusion criteria: Asthmatic patients symptomatic despite treatment with BDP or BUD 400 mcg/d Exclusion criteria: Not stated
Interventions	FP: 200 mcg/d (once daily) BUD: 400 mcg/d (once daily) Delivery device: not stated
Outcomes	Change in morning PEFR compared to baseline Asthma symptom score Daily use of beta2 agonists
Notes	Study in abstract form only Study also included a treatment arm with FP 100 mcg 2xdaily: results not considered
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Described as randomised; other information not available
Allocation concealment?	Unclear risk	Information not available
Blinding? All outcomes	Unclear risk	Information not available